期刊文献+

非小细胞肺癌驱动基因检测组织标本替代品的研究进展 被引量:1

Progress in Tissue Specimens Alternative for the Driver Genes Testing of Non-small Cell Lung Cancer
下载PDF
导出
摘要 基于驱动基因检测基础上的靶向药物治疗是目前晚期非小细胞肺癌的重要治疗手段。组织标本是驱动基因检测的金标准,但多数晚期肺癌患者无法获得足够的组织标本进行基因检测。探索组织标本替代品进行驱动基因检测是当前临床的热点问题。本文对驱动基因检测的组织替代标本进行综述。 Target treatment based on driver genes in advanced non-small cell lung cancer is very important currently. Tumor tissues is the gold standard for driver genes testing. However, most of patients could not get the gene information for lack of enough tissues. To explore the tissue specimens alternatives is a hot spot in clinical work. This report reviews the tissue specimen alternatives of driver gene testing in non-small cell lung cancer.
作者 孙燕 宋正波
出处 《中国肺癌杂志》 CAS CSCD 北大核心 2015年第6期387-390,共4页 Chinese Journal of Lung Cancer
基金 浙江省卫生计生委课题(No.2015KYA040)资助~~
关键词 肺肿瘤 基因检测 组织标本 Lung neoplasms Gene testing Tumor tissue
  • 相关文献

参考文献24

  • 1Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA CancerJ Clin, 2013, 63(1): 11-30.
  • 2Mok TSj Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10): 947-957.
  • 3Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N EnglJ Med, 2010j 362(25): 2380-2388.
  • 4Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol, 2007j 25(12): 1545-1552.
  • 5Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA, 2014, 311 (19): 1998-2006.
  • 6Xue C, Hu Z, Jiang w, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer, 2012, 77(2): 371-375.
  • 7Sepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non- small-ceU lung cancer. N EnglJ Med, 2005, 353(2): 123-132.
  • 8Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol, 2009, 2(16): 653-659.
  • 9Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol, 2013, 14(8): 777-786.
  • 10Oxnard GR, Paweletz CP, Kuang Yj et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next- generation genotyping of cell-free plasma DNA. Clin Cancer R.es, 2014, 20(6): 1698-1705.

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部